Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

962
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
962
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

499
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
499
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.0K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.0K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

795
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
795
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

477
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
477
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.2K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digital self-management programme for pain, fatigue and faecal incontinence in inflammatory bowel disease: cost-effectiveness analysis of the IBD-BOOST randomised controlled trial.

BMJ open gastroenterology·2026
Same author

Considerations in reviewing network meta-analyses of heterogeneous clinical trial designs: a methodological review in Crohn's disease and ulcerative colitis.

Crohn's & colitis 360·2026
Same author

High-dimensional single-cell mass cytometry analysis of IL-4 treated human macrophages reveals heterogeneity and a CD206high anticolitic subset.

Journal of leukocyte biology·2026
Same author

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.

Inflammatory bowel diseases·2026
Same author

Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial.

Crohn's & colitis 360·2026
Same author

Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study.

Therapeutic advances in gastroenterology·2026
Same journal

Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study.

Drugs in R&D·2026
Same journal

Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation.

Drugs in R&D·2026
Same journal

A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors.

Drugs in R&D·2026
Same journal

Ustekinumab in the Management of Perianal Fistulizing Crohn's Disease: Current Evidence and Practical Strategies.

Drugs in R&D·2026
Same journal

HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance.

Drugs in R&D·2026
Same journal

Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms.

Drugs in R&D·2026
See all related articles

Related Experiment Video

Updated: Jan 28, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.5K

Ulcerative Colitis: Shifting Sands.

Geert R A M D'Haens1, James O Lindsay2,3, Remo Panaccione4

  • 1Department of Gastroenterology, Academic Medical Center, Meibergdreef 9, 1100 DZ, Amsterdam, The Netherlands. g.dhaens@amc.uva.nl.

Drugs in R&D
|March 4, 2019
PubMed
Summary
This summary is machine-generated.

This review clarifies common misunderstandings about ulcerative colitis (UC) in adults. Addressing these misconceptions can help improve patient care and outcomes for this chronic inflammatory bowel disease.

More Related Videos

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K
Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
15:49

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System

Published on: October 16, 2013

32.6K

Related Experiment Videos

Last Updated: Jan 28, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.5K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K
Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
15:49

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System

Published on: October 16, 2013

32.6K

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Inflammatory Bowel Disease Research

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) with significant patient burden.
  • Current understanding and management of UC may be influenced by misconceptions.
  • Optimizing care requires addressing these prevalent misunderstandings.

Purpose of the Study:

  • To review and clarify common misconceptions regarding ulcerative colitis (UC) in adult patients.
  • To provide insights for improving the clinical management of UC.
  • To highlight areas where patient care can be enhanced by correcting misunderstandings.

Main Methods:

  • Review of current literature and clinical understanding of ulcerative colitis (UC).
  • Analysis of distinctions between UC and Crohn's disease (CD) phenotypes.
  • Examination of disease severity, extent, and treatment response in UC management.

Main Results:

  • Distinctions between UC and CD are not always clear, with potential for phenotype changes.
  • Distal UC can be as disabling as extensive disease, and severe proctitis significantly impacts quality of life.
  • Colorectal cancer (CRC) risk in UC is comparable to colonic CD; corticosteroid-free remission and biologic therapy effectiveness remain key challenges.

Conclusions:

  • Accurate understanding of UC disease manifestations, severity, and progression is crucial for effective patient management.
  • Achieving corticosteroid-free remission and optimizing biologic therapies are essential therapeutic goals in UC.
  • Addressing misconceptions can lead to improved quality of life and outcomes for adults with ulcerative colitis.